Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
FY2025 adjusted EBITA SEK 4.88bn, a 14.0% adjusted margin; organic growth 4.9%.
Band uses the adjusted margin; reported net sales and profit not yet captured.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
No adverse media involving Getinge found in HSH's search of the last 24 months.
Data breaches, cyber incidents, regulator action and assurance status.
No confirmed data breaches, cyber incidents or regulator action involving Getinge found in HSH's search of the last 24 months. Unverified claims on ransomware leak-site trackers are not included. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Jun 2026: Getinge subsidiary Maquet Cardiovascular began a US FDA Class II recall of 205 VasoView HemoPro 2 vessel-harvesting devices exposed to an out-of-specification sterilisation dose at a contract steriliser; users were told to quarantine affected units.
Contract delivery, go-lives, terminations and disputes.
Oct 2025: Aneurin Bevan University Health Board extended its rental of a Getinge mobile decontamination unit at Royal Gwent Hospital (about £87.6k ex VAT, to Apr 2026) by single tender waiver. No disputes or terminations found in HSH's search of the last 24 months.